Last reviewed · How we verify
Docetaxel, Cisplatin
Docetaxel and cisplatin work together as a chemotherapy combination: docetaxel stabilizes microtubules to prevent cell division, while cisplatin cross-links DNA to prevent replication, both inducing cancer cell death.
Docetaxel and cisplatin work together as a chemotherapy combination: docetaxel stabilizes microtubules to prevent cell division, while cisplatin cross-links DNA to prevent replication, both inducing cancer cell death. Used for Advanced or metastatic non-small cell lung cancer, Gastric cancer, Head and neck cancer.
At a glance
| Generic name | Docetaxel, Cisplatin |
|---|---|
| Also known as | Taxotere, Platinol |
| Sponsor | Samsung Medical Center |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Target | Beta-tubulin (docetaxel); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel is a taxane that binds to beta-tubulin and prevents microtubule depolymerization, disrupting the mitotic spindle and causing cell cycle arrest in G2/M phase. Cisplatin is a platinum-based alkylating agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Gastric cancer
- Head and neck cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Alopecia
- Mucositis
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
- Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) (PHASE2)
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Cisplatin CI brief — competitive landscape report
- Docetaxel, Cisplatin updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI